CN106102763A - 速效胰岛素制剂和药物递送系统 - Google Patents

速效胰岛素制剂和药物递送系统 Download PDF

Info

Publication number
CN106102763A
CN106102763A CN201580013125.0A CN201580013125A CN106102763A CN 106102763 A CN106102763 A CN 106102763A CN 201580013125 A CN201580013125 A CN 201580013125A CN 106102763 A CN106102763 A CN 106102763A
Authority
CN
China
Prior art keywords
insulin
pharmaceutical compositions
infusion
methods
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580013125.0A
Other languages
English (en)
Chinese (zh)
Inventor
杰弗里·I·约瑟夫
理查德·威廉·贝伦森
布鲁斯·弗兰克
迈克尔·A·韦斯
托马斯·哈迪尔
格雷戈里·杜北
陈志强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Searl Malin Diabetes LLC
Original Assignee
Searl Malin Diabetes LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searl Malin Diabetes LLC filed Critical Searl Malin Diabetes LLC
Publication of CN106102763A publication Critical patent/CN106102763A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/02—Holding devices, e.g. on the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/02—Holding devices, e.g. on the body
    • A61M2025/0253—Holding devices, e.g. on the body where the catheter is attached by straps, bands or the like secured by adhesives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
    • A61M2205/054—General characteristics of the apparatus combined with other kinds of therapy with electrotherapy
    • A61M2205/055—General characteristics of the apparatus combined with other kinds of therapy with electrotherapy with electrophoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502—User interfaces, e.g. screens or keyboards
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/201—Glucose concentration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
CN201580013125.0A 2014-01-13 2015-01-13 速效胰岛素制剂和药物递送系统 Pending CN106102763A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461926944P 2014-01-13 2014-01-13
US201461926946P 2014-01-13 2014-01-13
US61/926,944 2014-01-13
US61/926,946 2014-01-13
PCT/US2015/011202 WO2015106269A2 (en) 2014-01-13 2015-01-13 Rapid action insulin formulations and pharmaceutical delivery systems

Publications (1)

Publication Number Publication Date
CN106102763A true CN106102763A (zh) 2016-11-09

Family

ID=53524484

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580013125.0A Pending CN106102763A (zh) 2014-01-13 2015-01-13 速效胰岛素制剂和药物递送系统

Country Status (10)

Country Link
US (4) US9901622B2 (enExample)
EP (1) EP3094343A4 (enExample)
JP (3) JP6944780B2 (enExample)
KR (1) KR102351111B1 (enExample)
CN (1) CN106102763A (enExample)
AU (1) AU2015204491B2 (enExample)
BR (1) BR112016016290A2 (enExample)
CA (1) CA2936563A1 (enExample)
IL (1) IL246706B (enExample)
WO (1) WO2015106269A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108489941A (zh) * 2018-01-31 2018-09-04 吉林大学 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用
CN110198722A (zh) * 2016-11-21 2019-09-03 卡斯西部储备大学 稳定性增强的快速作用的胰岛素类似物
CN110582285A (zh) * 2017-05-05 2019-12-17 艾瑞克有限公司 稳定的胰岛素制剂
CN111989088A (zh) * 2018-04-04 2020-11-24 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1762259T3 (da) 2005-09-12 2011-01-03 Unomedical As Indføringsindretning til infusionssæt med en første og en anden fjederenhed
CA2792138A1 (en) 2010-03-30 2011-10-06 Unomedical A/S Medical device
WO2012123274A1 (en) 2011-03-14 2012-09-20 Unomedical A/S Inserter system with transport protection
WO2013050277A1 (en) 2011-10-05 2013-04-11 Unomedical A/S Inserter for simultaneous insertion of multiple transcutaneous parts
EP2583715A1 (en) 2011-10-19 2013-04-24 Unomedical A/S Infusion tube system and method for manufacture
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
AU2015204491B2 (en) 2014-01-13 2021-01-07 Thermalin Inc. Rapid action insulin formulations and pharmaceutical delivery systems
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
WO2016105545A2 (en) * 2014-12-24 2016-06-30 Case Western Reserve University Insulin analogues with enhanced stabilized and reduced mitogenicity
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
EP3405230A1 (en) 2016-01-19 2018-11-28 Unomedical A/S Cannula and infusion devices
WO2018165290A1 (en) * 2017-03-07 2018-09-13 Case Western Reserve University Single-chain insulin analogues stabilized by a fourth disulfide bridge
GB201707187D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
WO2018222787A1 (en) 2017-06-01 2018-12-06 Eli Lilly And Company Rapid-acting insulin compositions
WO2019050749A1 (en) * 2017-09-08 2019-03-14 Eli Lilly And Company PHARMACEUTICAL COMBINATIONS COMPRISING INSULIN AND AT LEAST ONE AGENT SELECTED AMONG MELOXICAM, BROMFENAC SODIUM, ACETYLSALICYLIC ACID, SALICYLIC ACID AND PARACETAMOL
CN113166223A (zh) * 2018-09-21 2021-07-23 卡斯西部储备大学 位点2单链胰岛素类似物
US20220235111A1 (en) * 2019-05-17 2022-07-28 Case Western Reserve University Variant Single-Chain Insulin Analogues
EP3972672A4 (en) 2019-05-20 2023-06-21 Unomedical A/S Rotatable infusion device and methods thereof
EP4051337A4 (en) * 2019-10-30 2023-11-01 Thermalin Inc. DRUG RELEASE SYSTEMS, DEVICES AND METHODS
NL2025679B1 (en) * 2020-05-26 2021-12-13 Johanna Daams Brechtje Electrical stimulation for preventing or treating nitric oxide deficiency related conditions
CA3190574A1 (en) 2020-08-23 2022-03-03 William Kenneth Ward Measurement of glucose near an insulin delivery catheter by minimizing the adverse effects of insulin preservatives: alternative ligands and redox mediator metals
US20220386905A1 (en) * 2021-03-02 2022-12-08 Pacific Diabetes Technologies Inc Signal processing algorithm for improving accuracy of a continuous glucose sensor and a combined continuous glucose sensor and insulin delivery cannula
KR102678960B1 (ko) * 2021-08-26 2024-06-27 주식회사 에이피알 바디 관리기
US20240149021A1 (en) * 2022-11-04 2024-05-09 Becton, Dickinson And Company Intravenous Catheter Securement Sleeve
US20240216649A1 (en) * 2023-01-03 2024-07-04 Becton, Dickinson And Company Management of Catheters and Accessories During Intravascular Catheter Maintenance
US20250242110A1 (en) * 2024-01-26 2025-07-31 Medtronic Minimed, Inc. Fluid delivery filters

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1116629A (zh) * 1994-06-16 1996-02-14 伊莱利利公司 单体胰岛素类似物制剂
WO2008121256A1 (en) * 2007-03-30 2008-10-09 Instrumentation Laboratory Company Adaptor for sample vial
CN101883609A (zh) * 2007-10-09 2010-11-10 百达尔公司 可注射的速效胰岛素组合物
CN102171245A (zh) * 2008-07-31 2011-08-31 卡斯西部储备大学 卤素稳定型胰岛素
CN102341119A (zh) * 2009-03-03 2012-02-01 百达尔公司 供快速吸收的胰岛素制剂
WO2013158618A1 (en) * 2012-04-16 2013-10-24 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
WO2014116753A1 (en) * 2013-01-22 2014-07-31 Case Western Reserve University N-terminal truncated insulin analogues

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK134691D0 (da) * 1991-07-12 1991-07-12 Novo Nordisk As Apparat
CO4750643A1 (es) * 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
EP1196445A1 (en) * 1999-06-29 2002-04-17 Eli Lilly And Company Insulin crystals for pulmonary administration
WO2003053460A1 (en) * 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
CA2649109A1 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
WO2009132129A2 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
WO2011072288A2 (en) 2009-12-11 2011-06-16 Case Western Reserve University Insulin analogues with chlorinated amino acids
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
KR20120129875A (ko) * 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
CA2747490C (en) * 2008-12-19 2017-02-14 Indiana University Research And Technology Corporation Insulin analogs
US20120184488A1 (en) 2009-09-01 2012-07-19 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
KR20130043085A (ko) 2010-02-22 2013-04-29 케이스 웨스턴 리저브 유니버시티 가용성 및 결정 형태의 지속형 인슐린 유사체 제제
US9487572B2 (en) 2011-07-13 2016-11-08 Case Western Reserve University Non-standard insulin analogues
US9908925B2 (en) 2011-10-27 2018-03-06 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
AU2012332556B2 (en) * 2011-10-31 2016-05-26 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
US20150299286A1 (en) 2012-01-20 2015-10-22 Case Western Reserve University Glutamic acid-stabilized insulin analogues
US9624287B2 (en) 2012-07-17 2017-04-18 Case Western Reserve University O-linked carbohydrate-modified insulin analogues
AU2013337250B2 (en) 2012-11-05 2017-06-22 Case Western Reserve University Long-acting single-chain insulin analogues
AU2014232894B2 (en) 2013-03-15 2018-02-08 Case Western Reserve University Site 2 insulin analogues
AU2015204491B2 (en) 2014-01-13 2021-01-07 Thermalin Inc. Rapid action insulin formulations and pharmaceutical delivery systems
JP6829928B2 (ja) 2014-10-06 2021-02-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 二相性単鎖インスリン類似体
CA2964918A1 (en) 2014-10-20 2016-04-28 Case Western Reserve University Halogenated insulin analogues of enhanced biological potency
WO2016105545A2 (en) 2014-12-24 2016-06-30 Case Western Reserve University Insulin analogues with enhanced stabilized and reduced mitogenicity
JP2018505874A (ja) 2015-01-20 2018-03-01 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 選択的シグナリング特性及びより低い分裂促進性を有するインスリンアナログ

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1116629A (zh) * 1994-06-16 1996-02-14 伊莱利利公司 单体胰岛素类似物制剂
WO2008121256A1 (en) * 2007-03-30 2008-10-09 Instrumentation Laboratory Company Adaptor for sample vial
CN101883609A (zh) * 2007-10-09 2010-11-10 百达尔公司 可注射的速效胰岛素组合物
CN102171245A (zh) * 2008-07-31 2011-08-31 卡斯西部储备大学 卤素稳定型胰岛素
CN102341119A (zh) * 2009-03-03 2012-02-01 百达尔公司 供快速吸收的胰岛素制剂
WO2013158618A1 (en) * 2012-04-16 2013-10-24 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
WO2014116753A1 (en) * 2013-01-22 2014-07-31 Case Western Reserve University N-terminal truncated insulin analogues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALAN KRASNER等: "A Review of a Family of Ultra-Rapid-Acting Insulins: Formulation Development", 《J DIABETES SCI TECHNOL》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110198722A (zh) * 2016-11-21 2019-09-03 卡斯西部储备大学 稳定性增强的快速作用的胰岛素类似物
CN110582285A (zh) * 2017-05-05 2019-12-17 艾瑞克有限公司 稳定的胰岛素制剂
CN110582285B (zh) * 2017-05-05 2023-04-14 艾瑞克有限公司 稳定的胰岛素制剂
CN108489941A (zh) * 2018-01-31 2018-09-04 吉林大学 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用
CN108489941B (zh) * 2018-01-31 2021-07-27 吉林大学 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用
CN111989088A (zh) * 2018-04-04 2020-11-24 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统

Also Published As

Publication number Publication date
US10561711B2 (en) 2020-02-18
JP6944780B2 (ja) 2021-10-06
WO2015106269A2 (en) 2015-07-16
KR102351111B1 (ko) 2022-01-14
US20160375104A1 (en) 2016-12-29
WO2015106269A3 (en) 2015-10-22
US20210386831A1 (en) 2021-12-16
JP2017505338A (ja) 2017-02-16
US20180243380A1 (en) 2018-08-30
JP2020189875A (ja) 2020-11-26
US20200138911A1 (en) 2020-05-07
CA2936563A1 (en) 2015-07-16
US9901622B2 (en) 2018-02-27
EP3094343A4 (en) 2017-10-18
IL246706A0 (en) 2016-08-31
BR112016016290A2 (pt) 2017-10-03
AU2015204491B2 (en) 2021-01-07
JP2019081773A (ja) 2019-05-30
EP3094343A2 (en) 2016-11-23
AU2015204491A1 (en) 2016-08-18
WO2015106269A8 (en) 2016-08-18
KR20160122145A (ko) 2016-10-21
IL246706B (en) 2020-04-30

Similar Documents

Publication Publication Date Title
CN106102763A (zh) 速效胰岛素制剂和药物递送系统
JP5351884B2 (ja) インスリン分泌促進性ペプチドの懸濁製剤及び使用
ES2365410T3 (es) Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
ES2534596T3 (es) Solución para infusión e inyección de levodopa
JP2017505338A5 (enExample)
CA2491682A1 (en) Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine
US20060287372A1 (en) Pharmaceutical preparations containing thiazolidinediones showing new therapeutic indications
KR102833828B1 (ko) 인슐린 화합물의 전달을 위한 의료용 주입 펌프 시스템
CN101095942A (zh) 一种包含稳定剂的Exendin注射剂药物配方
US20200000890A1 (en) Use of apc analogue for wound healing
IL277720B2 (en) Medical infusion pump system for the delivery of an insulin compound
KR20230146645A (ko) 인크레틴 유사체-함유 조성물 및 그의 용도
US20050118241A1 (en) Platform for transdermal formulations (ptf)
WO2016001185A1 (en) Dosage regimen for the treatment of diabetes
US20250276127A1 (en) Therapeutic methods and devices
RU2146884C1 (ru) Способ лечения диффузного токсического зоба
Sherr et al. Future Drug Treatments for Type 1 Diabetes
Kulkarni et al. Insulin Therapy for Diabetes: Current Scenario and Future Perspectives
KR20230040943A (ko) 1형 당뇨병에 대한 우수한 혈당 제어를 제공하기 위한 인간 아밀린 유사체 폴리펩타이드의 용도
HK1151241B (en) Enhancement of the efficacy of therapeutic proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20161109